AbCellera Biologics Expands Partnership and Advances Pipeline
Company Announcements

AbCellera Biologics Expands Partnership and Advances Pipeline

AbCellera Biologics ( (ABCL) ) has shared an update.

AbCellera reported its Q3 2024 financial results, highlighting a strategic expansion with Eli Lilly for antibody discovery in key therapeutic areas. Despite a slight dip in revenue to $6.5 million, the company bolstered its R&D efforts with increased expenses of $41 million, aiming to advance its internal pipeline. AbCellera achieved 95 partner-initiated program starts and advanced 14 molecules to clinical stages, reflecting robust growth and a focus on future clinical trials.

See more insights into ABCL stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAbCellera presents data on applications of T-cell engager platform at SITC
TipRanks Auto-Generated NewsdeskAbCellera Biologics Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App